Lemtrada Panel Review Pivots On What Constitutes An Adequate, Well-Controlled Trial
This article was originally published in The Pink Sheet Daily
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will be asked whether open-label, rater-blinded trials meet approval standards for Sanofi/Genzyme’s Lemtrada sBLA; agency reviewers say no.
You may also be interested in...
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.
Siga CSO Dennis Hruby talked with the Pink Sheet about the company’s plans for development of Tpoxx for monkeypox in the US. If the necessary emergency declaration is made that would let FDA issue EUAs, the company would likely try to apply with its current clinical trial-less data set.
Biden administration will run out of supply of Lilly’s covid antibody bebtelovimab in August, forcing a shift to commercial market due to lack of funds. The transition will require changes to the emergency use authorization and involve a price hike.